CO7101191A2 - Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo - Google Patents

Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo

Info

Publication number
CO7101191A2
CO7101191A2 CO14146333A CO14146333A CO7101191A2 CO 7101191 A2 CO7101191 A2 CO 7101191A2 CO 14146333 A CO14146333 A CO 14146333A CO 14146333 A CO14146333 A CO 14146333A CO 7101191 A2 CO7101191 A2 CO 7101191A2
Authority
CO
Colombia
Prior art keywords
novel
preparation
platform system
anthobiotic
system based
Prior art date
Application number
CO14146333A
Other languages
English (en)
Inventor
Xiaoqing Qiu
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of CO7101191A2 publication Critical patent/CO7101191A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Se proporcionan un método de preparación de antibiótico novedoso y sistema de plataforma en función del método, que pertenece a un método de desarrollo de fármaco novedoso. El método se basa en una fórmula estructural fija: F-R, en donde F es un área de efecto, y R es un área de identificación. En el nivel anterior, la presente invención puede desarrollar rápidamente un antibiótico novedoso específico para la mayoría de microorganismos patogénicos o células biológicas, También se proporciona una plataforma para implementar el método, asegurando que se desarrolla el antibiótico novedoso en un proceso simplificado eficiente.
CO14146333A 2011-12-08 2014-07-08 Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo CO7101191A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110405775 2011-12-08

Publications (1)

Publication Number Publication Date
CO7101191A2 true CO7101191A2 (es) 2014-10-31

Family

ID=48573572

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14146333A CO7101191A2 (es) 2011-12-08 2014-07-08 Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo

Country Status (21)

Country Link
US (1) US10071358B2 (es)
EP (1) EP2789632B1 (es)
JP (2) JP2015507471A (es)
KR (2) KR101916205B1 (es)
CN (1) CN103159856B (es)
AP (1) AP2014007769A0 (es)
AU (1) AU2012349080B2 (es)
BR (1) BR112014013735A2 (es)
CA (1) CA2857976A1 (es)
CO (1) CO7101191A2 (es)
DK (1) DK2789632T3 (es)
EA (1) EA201400634A1 (es)
ES (1) ES2686341T3 (es)
HK (1) HK1197247A1 (es)
IL (1) IL232995B (es)
IN (1) IN2014KN01420A (es)
PH (1) PH12014501276A1 (es)
SG (1) SG11201402990YA (es)
TW (1) TWI557225B (es)
WO (1) WO2013083095A1 (es)
ZA (1) ZA201404527B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
CN102747041B (zh) * 2011-04-21 2014-07-16 畿晋庆三联（北京）生物技术有限公司 抗蓝藻重组抗体多肽及其基因与制备方法
CN108341869A (zh) * 2016-12-26 2018-07-31 畿晋庆三联（北京）生物技术有限公司 抗结核分枝杆菌（Mycobacterium tuberculosis）及其感染的药物及其应用
US11125750B2 (en) * 2018-06-28 2021-09-21 The University Of Toledo Methods, assays and kits for detecting exposure to cyanotoxins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1274829C (zh) 2004-12-10 2006-09-13 四川大学华西医院 抗eb病毒所致肿瘤多肽及其应用与制备方法
DE102007036128A1 (de) * 2007-07-23 2009-02-12 Universität Leipzig Antibiotische Peptide
CN101200727B (zh) 2007-12-21 2013-06-26 畿晋庆堂国际生物技术有限公司 抗农作物真菌多肽及其制备方法
CN101215568B (zh) * 2008-01-18 2010-06-23 畿晋庆三联（北京）生物技术有限公司 抗炭疽多肽及其应用与制备方法
CN101643501B (zh) 2008-11-07 2012-06-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗生素及其核苷酸序列、制备方法与应用
CN101633699B (zh) 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用
CN102101888B (zh) * 2009-12-17 2013-03-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法
CN102747041B (zh) 2011-04-21 2014-07-16 畿晋庆三联（北京）生物技术有限公司 抗蓝藻重组抗体多肽及其基因与制备方法

Also Published As

Publication number Publication date
JP6412077B2 (ja) 2018-10-24
TW201331363A (zh) 2013-08-01
TWI557225B (zh) 2016-11-11
CA2857976A1 (en) 2013-06-13
CN103159856B (zh) 2015-02-25
IN2014KN01420A (es) 2015-10-23
PH12014501276A1 (en) 2014-09-08
US10071358B2 (en) 2018-09-11
KR101916205B1 (ko) 2018-11-08
AU2012349080B2 (en) 2016-06-02
KR20160130531A (ko) 2016-11-11
CN103159856A (zh) 2013-06-19
IL232995A0 (en) 2014-07-31
NZ627116A (en) 2016-07-29
ES2686341T3 (es) 2018-10-17
SG11201402990YA (en) 2014-09-26
DK2789632T3 (en) 2018-08-06
AP2014007769A0 (en) 2014-07-31
HK1197247A1 (en) 2015-01-09
JP2015507471A (ja) 2015-03-12
IL232995B (en) 2018-01-31
EA201400634A1 (ru) 2014-12-30
AU2012349080A1 (en) 2014-07-24
ZA201404527B (en) 2017-04-26
KR20140104475A (ko) 2014-08-28
EP2789632B1 (en) 2018-06-06
WO2013083095A1 (zh) 2013-06-13
EP2789632A1 (en) 2014-10-15
JP2017023150A (ja) 2017-02-02
BR112014013735A2 (pt) 2017-06-13
US20140349880A1 (en) 2014-11-27
EP2789632A4 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
DOP2013000030A (es) Compuesto heterociclico y su uso
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
SV2015004979A (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contiene un grupo sulfoximina
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
AR091776A1 (es) Herramienta de deformacion desintegrable
CL2019002135A1 (es) Células microbianas, métodos para producir las mismas, y usos de las mismas.
CO6440530A2 (es) Formulaciones de caldo de fermentación
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
BR112015006524A2 (pt) derivados de quinazolinona como inibidores de parp
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
CO7101191A2 (es) Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
BR112013033759A8 (pt) Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol
UY35439A (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo.
BR112015030431A2 (pt) formulação de liberação modificada